Our study is a real-life, multicenter analysis that investigates the relationship between inflammatory and nutritional biomarkers and pathological complete response in patients with HER2-positive breast cancer undergoing neoadjuvant HER2-targeted therapy. Here, ERBB2 is linked to breast carcinoma.